PURPOSE 2 will test whether an investigational PrEP (pre-exposure prophylaxis) medicine, lenacapavir, helps reduce the chance of getting HIV through sex. PURPOSE 2 FAQs · About the Study · Purpose 3 · Study Locations

PURPOSE 2 is evaluating an investigational drug, lenacapavir, and enrolled cisgender men, transgender women, transgender men, and gender non-binary individuals ... Purpose 2 · PURPOSE 2 FAQs · About the Study · Purpose 1

12 сент. 2024 г. · The study evaluated the safety and efficacy of twice-yearly injectable lenacapavir for PrEP compared to once-daily oral emtricitabine/tenofovir ...

13 нояб. 2024 г. · PURPOSE 2 is the second pivotal Phase 3 trial to demonstrate superior efficacy for twice-yearly lenacapavir for the investigational use of HIV ...

26 сент. 2024 г. · The PURPOSE 2 trial reported a 96% reduction in the risk of acquiring HIV among study participants, with 99.9% of individuals using LEN not ...

PURPOSE 2 is a study to find out if long-acting, injectable (given as a shot) lenacapavir for PrEP is safe and acceptable for adolescents.

Lenacapavir, given as a 6-monthly subcutaneous injection after a short oral lead-in, was also significantly more effective in PURPOSE 2 than the control arm ...

12 сент. 2024 г. · The study evaluated the safety and efficacy of twice-yearly injectable lenacapavir for PrEP compared to once-daily oral emtricitabine/tenofovir ...

7 окт. 2024 г. · PURPOSE 2 is a Phase 3, double-blind, multicenter, randomized study evaluating the safety and efficacy of twice-yearly subcutaneous ...

3 окт. 2024 г. · PURPOSE 2 is the sister study to PURPOSE 1, which looked at adult women and girls in Sub-Saharan Africa, and found that lenacapavir was superior ...